Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Cash & Equivalents (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Cash & Equivalents for 4 consecutive years, with $7.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Equivalents rose 917.74% to $7.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $7.7 million, a 917.74% increase, with the full-year FY2024 number at $1.1 million, down 60.83% from a year prior.
  • Cash & Equivalents was $7.7 million for Q3 2025 at bioAffinity Technologies, up from $802835.0 in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $13.5 million in Q3 2022 to a low of $400000.0 in Q1 2025.
  • A 4-year average of $5.0 million and a median of $2.8 million in 2023 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: crashed 90.32% in 2024, then skyrocketed 917.74% in 2025.
  • bioAffinity Technologies' Cash & Equivalents stood at $11.4 million in 2022, then tumbled by 75.28% to $2.8 million in 2023, then plummeted by 60.83% to $1.1 million in 2024, then skyrocketed by 596.65% to $7.7 million in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Cash & Equivalents are $7.7 million (Q3 2025), $802835.0 (Q2 2025), and $400000.0 (Q1 2025).